(ROIV) – Hot Comments
-
Guggenheim reiterates Buy rating on Tourmaline Bio (TRML), "news is likely to increase investors' perceived risk"
-
Guggenheim Starts Roivant Sciences (ROIV) at Buy, '4Q23 should be a big potential catalyst'
-
-
-
-
-
-
Back to ROIV Stock Lookup